SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.43 CNY | -1.07% |
|
+1.09% | -7.12% |
| May. 14 | GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… | RE |
| Apr. 29 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
China accounts for 96.6% of net sales.
Number of employees: 3,254
Sales per Business
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Albumin - Imported
44.0
%
| 2,734 | 41.6 % | 3,504 | 44.0 % | +28.16% |
Intravenous Injection
22.7
%
| 1,313 | 20.0 % | 1,805 | 22.7 % | +37.47% |
Albumin - Self-produced
18.0
%
| 1,489 | 22.7 % | 1,431 | 18.0 % | -3.94% |
Other Blood Products
13.6
%
| 968 | 14.7 % | 1,081 | 13.6 % | +11.68% |
Testing Equipment and Reagents
1.8
%
| 61 | 0.9 % | 141 | 1.8 % | +131.25% |
Other Business
0.0
%
| 1 | 0.0 % | 2 | 0.0 % | +19.10% |
Sales per region
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
China
100.0
%
| 6,567 | 100.0 % | 7,964 | 100.0 % | +21.27% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 21-10-25 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
Hong Qiu
IRC | Investor Relations Contact | - | - |
Ji Hui Chen
PRN | Corporate Officer/Principal | 58 | 04-04-30 |
Hui Lu
PRN | Corporate Officer/Principal | 49 | 09-04-30 |
Zheng Liu
SEC | Corporate Secretary | 54 | 07-04-26 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20-05-19 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 07-04-26 |
David Bell
BRD | Director/Board Member | 70 | 20-05-19 |
Ya Min Chen
BRD | Director/Board Member | 72 | 22-06-13 |
| Director/Board Member | 57 | 20-05-20 | |
Binh Hoang
BRD | Director/Board Member | 50 | 07-04-26 |
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
Yao Li
BRD | Director/Board Member | 61 | 07-04-26 |
Ling Peng
BRD | Director/Board Member | 45 | 20-05-19 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 6,645,480,758 | 4,620,597,277 ( 69.53 %) | 9,495,921 ( 0.1429 %) | 69.53 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 39,960,800 | 1.87% | 89,672,435 $ |
Company contact information
Shanghai RAAS Blood Products Co., Ltd.
2009 Wangyuan Road Biotechnology Park
201401, Shanghai
+
http://www.raas-corp.com
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.51
CNY
Average target price
6
CNY
Spread / Average Target
-20.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.12% | 6.86B | |
| -1.26% | 89.46B | |
| +2.76% | 40.74B | |
| -12.32% | 33.03B | |
| +54.44% | 24.68B | |
| -17.39% | 15.12B | |
| -9.14% | 12.81B | |
| -10.48% | 11.79B | |
| -42.45% | 11.64B | |
| +7.34% | 8.9B |
- Stock Market
- Equities
- 002252 Stock
- Company Shanghai RAAS Blood Products Co., Ltd.
